Krish Patel, MD, discusses the factors to consider when treating patients with relapsed and/or refractory follicular lymphoma.
Krish Patel, MD, director, Lymphoma Program, Hematologic Malignancies and Cellular Therapy, Swedish Cancer Institute, discusses the factors to consider when treating patients with relapsed and/or refractory follicular lymphoma.
Many therapies have been developed in recent years for relapsed/refractory follicular lymphoma, making it important to consider the length of a patient’s initial remission after frontline treatment, Patel says. Understanding how long a patient’s remission lasted, as well as a patient’s comorbidities, is critical when assessing clinical factors ahead of treatment, Patel explains. Consulting a patient on their willingness to accept certain risks and toxicities is also critical in this space, Patel adds.
Additionally, treatments have different types of adverse effects and risks associated with them, underscoring these considerations, Patel continues. Overall, there are a lot of factors to consider given all the tools available for treating relapsed and refractory follicular lymphoma, Patel concludes.